INGELHEIM, Germany - Thursday, August 15th 2013 [ME NewsWire]
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™ 1 and 2 trials
The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis
The milestone coincides with the New England Journal of Medicine publication of SOUND-C2: one of the largest interferon-free studies in genoytpe-1 HCV published to date, forming the basis of the HCVerso™ trials
(BUSINESS WIRE)
For media outside USA, UK and Canada only
Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.1,2 The trials are investigating the efficacy and safety of Boehringer Ingelheim’s second generation protease inhibitor faldaprevir* and NS5B polymerase inh
...
Read more »